Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 0.38 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571083 | 1.00 | TGFBR1 (0.38) | TGFBR1STSIDH1EPHX2GPR55 | |
| SCHEMBL29570536 | 0.93 | TGFBR1 (0.43) | TGFBR1STSLMNAPOLBSMN1; SMN2 | |
| SCHEMBL29571019 | 0.93 | TGFBR1 (0.43) | TGFBR1STSLMNAPOLBSMN1; SMN2 | |
| SCHEMBL24326087 | 0.93 | TGFBR1 (0.43) | TGFBR1STSLMNAPOLBSMN1; SMN2 | |
| SCHEMBL24326268 | 0.93 | TGFBR1 (0.43) | TGFBR1STSLMNAPOLBSMN1; SMN2 | |
| SCHEMBL24326411 | 0.90 | TGFBR1 (0.42) | TGFBR1STSLMNAPOLBSMN1; SMN2 | |
| SCHEMBL29570518 | 0.90 | TGFBR1 (0.42) | TGFBR1STSLMNAPOLBSMN1; SMN2 | |
| SCHEMBL24325433 | 0.83 | EPHX2 (0.37) | IDH1EPHX2POLBKMT2A | |
| SCHEMBL24326078 | 0.83 | EPHX2 (0.37) | IDH1EPHX2POLBKMT2A | |
| SCHEMBL24325731 | 0.82 | LMNA (0.40) | LMNAPOLBSMN1; SMN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TGFBR1 532/4885STS 3208/4885IDH1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.